Johan Luthman, Lundbeck EVP R&D, on Rebuilding Neuroscience Pipelines & Drug Discovery
Episode
31 min
Read time
2 min
Topics
Productivity, Relationships, Investing
AI-Generated Summary
Key Takeaways
- ✓R&D Productivity Formula: Luthman applies a framework borrowed from Eli Lilly where productivity equals (number of assets × PTRS × market value) divided by (time × money). He prioritizes increasing PTRS — probability of technical and regulatory success — above all else, treating time as the second lever and money as the least critical variable in the equation.
- ✓Phase 1b Patient Studies as Risk Reduction: Before entering Phase 2, Lundbeck runs Phase 1b studies in patients to confirm target occupancy and biological effect in humans. This "let the molecules speak early" approach generates proof-of-concept data that reduces late-stage failure risk and avoids the largest cost in drug development — opportunity cost from failed Phase 3 trials.
- ✓Biology Over Disease Modeling: Luthman instructs researchers to model biological mechanisms rather than diseases, particularly in psychiatry where animal models of conditions like depression lack validity. This reframe generates measurable biomarkers tied to genetic and mechanistic validation, enabling more rigorous go/no-go decisions before committing significant capital to clinical programs.
- ✓Portfolio Budget Reallocation: When Luthman joined Lundbeck, 65% of the R&D budget was allocated to lifecycle management of existing drugs, leaving only 5–7% for genuine innovation. Redirecting that spend toward early-stage external partnerships, preclinical acquisitions, and novel mechanism programs — including the Alder Biotherapeutics acquisition for monoclonal antibody capability — rebuilt the pipeline within seven years.
- ✓Foundation Ownership as Strategic Advantage: Lundbeck's foundation ownership structure eliminates hostile acquisition risk and enforces long-term thinking, with profits funding Danish academic research grants and the Brain Prize — neuroscience's equivalent of the Nobel. This structure allows R&D leadership to pursue multi-year rare disease and novel mechanism programs without short-term shareholder pressure disrupting pipeline strategy.
What It Covers
Johan Luthman, EVP of R&D at Lundbeck, details how he rebuilt the company's neuroscience pipeline from near-zero innovation spend, using a focused biology-first strategy, early proof-of-concept studies, and targeted acquisitions to generate multiple novel mechanism validations in humans over four years.
Key Questions Answered
- •R&D Productivity Formula: Luthman applies a framework borrowed from Eli Lilly where productivity equals (number of assets × PTRS × market value) divided by (time × money). He prioritizes increasing PTRS — probability of technical and regulatory success — above all else, treating time as the second lever and money as the least critical variable in the equation.
- •Phase 1b Patient Studies as Risk Reduction: Before entering Phase 2, Lundbeck runs Phase 1b studies in patients to confirm target occupancy and biological effect in humans. This "let the molecules speak early" approach generates proof-of-concept data that reduces late-stage failure risk and avoids the largest cost in drug development — opportunity cost from failed Phase 3 trials.
- •Biology Over Disease Modeling: Luthman instructs researchers to model biological mechanisms rather than diseases, particularly in psychiatry where animal models of conditions like depression lack validity. This reframe generates measurable biomarkers tied to genetic and mechanistic validation, enabling more rigorous go/no-go decisions before committing significant capital to clinical programs.
- •Portfolio Budget Reallocation: When Luthman joined Lundbeck, 65% of the R&D budget was allocated to lifecycle management of existing drugs, leaving only 5–7% for genuine innovation. Redirecting that spend toward early-stage external partnerships, preclinical acquisitions, and novel mechanism programs — including the Alder Biotherapeutics acquisition for monoclonal antibody capability — rebuilt the pipeline within seven years.
- •Foundation Ownership as Strategic Advantage: Lundbeck's foundation ownership structure eliminates hostile acquisition risk and enforces long-term thinking, with profits funding Danish academic research grants and the Brain Prize — neuroscience's equivalent of the Nobel. This structure allows R&D leadership to pursue multi-year rare disease and novel mechanism programs without short-term shareholder pressure disrupting pipeline strategy.
Notable Moment
Luthman recounts that both AstraZeneca and early pharma analysts dismissed multiple sclerosis as a market too small to pursue. Within five years of his departure from that program, MS had grown into a sixteen-billion-dollar market — a pattern he consciously repeated when entering migraine prevention at Lundbeck.
Episode Transcript
Hello, and welcome to the BioTech two thousand and fifty podcast. BioTech two thousand and fifty is a think tank chronicling the disruptions changing the biotech industry over the next several decades. Check out our website at biotech2050.com. Really excited today to host our first podcast recording here at JPM twenty twenty six in San Francisco. My name is Alok Tahey. I'm the cohost of biotech twenty fifty. My background is as a scientist, and I run Vibe Bio. Vibe is an AI platform focused on strategic decisions in pharma. I'm really excited today to be joined by Johan Luthman, the EVP of r and d at Lundbeck. We're gonna have a very interesting dialogue here in person person about his background and what brought him to Lundbeck today, their pipeline and potential, but then most importantly, what he thinks about the future of neuroscience and everything that's going on in the biotech world. Johan, thanks so much for joining us today. Yeah. Thank you for inviting me, Anders. I'm happy to be here and to be your first movie star is is a great opportunity. Right? You can only approve it after this. Right? Yeah. Indeed. Well, you know, maybe to kick us off, would love it if you can share a bit about your background, how you got to where you are today, and your journey at Lundbeck. Happy to do that. You know, obviously, I've been in the business for some time, and I worked in many different companies over the years. But I started up my career as a student in Stockholm, Sweden at the Karolinska Institute, Swedish by background. And I have studied dentistry, medicine, and also got a PhD in neuroscience at Helsinki Institute. And, had no plans to go into industry. I was thinking about doing good deeds in mid medicine and maybe third world medicine, etcetera. I loved surgery. I did a lot of that stuff and combining maxillofacial surgery and medicine. So that was my career. But I got that neuroscience PhD and it was more basic science work. So it was cell work and animal work, etcetera, and ended up in a postdoc position in Denver, Colorado in psychiatry pharmacology. And then I got a phone call from one of my former advisors who said, do you like to join what was then Astra? And I said, no, thank you. I'm doing fine. A year later, he called me again, in Denver. I was sitting in my office there doing some analytical work on some data, and now I had a baby. Wow. And I thought going back so I was planning going back to Sweden to finish my internship in medicine. And I thought maybe I should make some good money some years and then go back and finish up. And here I am. Well, over thirty years here. I never got back. It was all time. I mean, maybe I'm probably not a good clinician, but, there was …
Get the full transcript (5,925 words) + summary by email — free
One-time email with the complete transcript and AI summary of this episode. No account needed.
One email, no spam. We’ll also show you what SignalCast does.
You just read a 3-minute summary of a 28-minute episode.
Get Biotech 2050 Podcast summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from Biotech 2050 Podcast
Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery
Aug 3 · 47 min
Beyond Biotech
De-risking neurology drug development with better mouse models
Jun 26
More from Biotech 2050 Podcast
Robert Jacks, CEO of Sparrow Pharmaceuticals | Precision Medicine, Biotech Strategy & Leadership
Jul 22 · 34 min
NVIDIA AI Podcast
Snap’s Secret to Processing 10 Petabytes a Day: GPU-Accelerated Spark | NVIDIA AI Podcast Ep. 298
May 13
More from Biotech 2050 Podcast
We summarize every new episode. Want them in your inbox?
Nick Myerberg, Partner & Head of AI at Braidwell on AI's Next Era in Drug Discovery
Robert Jacks, CEO of Sparrow Pharmaceuticals | Precision Medicine, Biotech Strategy & Leadership
Ardelyx Leaders Mike Raab & Laura Williams on Building Biotech Around Patients
Acadia CEO Catherine Owen Adams on Neurodegeneration, AI & Building Biotech Vision
Barry Quart, CEO of Connect Biopharma, on Asthma Innovation & Biotech Leadership
Similar Episodes
Related episodes from other podcasts
Beyond Biotech
Jun 26
De-risking neurology drug development with better mouse models
NVIDIA AI Podcast
May 13
Snap’s Secret to Processing 10 Petabytes a Day: GPU-Accelerated Spark | NVIDIA AI Podcast Ep. 298
20VC (20 Minute VC)
Apr 27
20VC: Applovin: $160BN Market Cap, $5.48BN Revenue, $10M EBITDA Per Head | Why the Best Do Not Need Mentorship | Why Founders Should Not Angel Invest | Why Kindness in Business Will Slow You Down with Adam Foroughi
20VC (20 Minute VC)
Apr 11
20Sales: ElevenLabs: Why We Set a 20x Sales Quota | How to Structure Sales Compensation Plans | Customer Success: 'Total BS' or Growth Engine? | Building an AI Sales Machine: What Tools & Tactics Must CROs Adopt Today with Carles Reina
Beyond Biotech
Mar 27
HaemaLogiX - precision immunotherapy for multiple myeloma
Explore Related Topics
This podcast is featured in Best Biotech Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Investing & Markets Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into Biotech 2050 Podcast.
Every Monday, we deliver AI summaries of the latest episodes from Biotech 2050 Podcast and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime